Docetaxel Weekly with Metastatic Breast Cancer
- 1 September 2007
- journal article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 30 (8-9), 407-408
- https://doi.org/10.1159/000106841
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast CancerOncology Research and Treatment, 2007
- Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)Journal of Clinical Oncology, 2007
- Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast CancerThe Oncologist, 2005
- A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancerAnnals of Oncology, 2004
- CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBCJournal of Clinical Oncology, 2004